Adjunctive Ketamine With Relapse Prevention-Based Psychological Therapy in the Treatment of Alcohol Use Disorder
March 25, 2022 DOI: 10.64239/pi-qt3704 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Pilot trial Pilot study |
|---|---|
| Population | People with alcohol use disorder |
| Interventions | Ketamine mindfulness psychotherapy placebo alcohol psychoeducation |
| Topics | Addiction Esketamine Ketamine |
| Key findings | Ketamine plus mindfulness psychotherapy was more effective for sustained abstinence from alcohol than placebo plus alcohol psychoeducation. |
Abstract
Ketamine plus mindfulness psychotherapy was more effective for sustained abstinence from alcohol than placebo plus alcohol psychoeducation. Other combinations of these therapies were not significantly different from one another in this small pilot trial (N=20-25 in each group). Adverse effects were minimal, suggesting that current alcohol use is not a contraindication for consideration of ketamine.
Comparable studies
Other non-randomized and open-label trials on ketamine for addiction, most cited first.
| Study | Year | Design | Participants |
|---|---|---|---|
| Ketamine Psychedelic Therapy (KPT): A Review of the Results of Ten Years of Research Alcoholic patients | 1997 | Controlled clinical trial | n = 211 |
| Ketamine Therapy in Patients of Alcohol Use Disorder: A Prospective Pilot Study to Evaluate Abstinence Rate with This Add-on Treatment Modality Individuals with alcohol use disorder | 2024 | Pre-post intervention study | n = 18 |
| Acute Subjective Experiences of Intravenous Ketamine Therapy Among Medically Hospitalized Patients with Alcohol Use Disorder. Inpatients with alcohol use disorder receiving intravenous ketamine therapy | 2024 | Secondary analysis of clinical trial data with directed content analysis | n = 12 |
| The Montreal model of ketamine-therapy for alcohol use disorder and comorbid treatment-resistant depression: protocol for a feasibility trial Adults diagnosed with both alcohol use disorder and treatment-resistant depression | 2026 | Single-group, open-label feasibility trial | n = 30 |
| Ketamine to enhance methadone treatment retention in patients with opioid use disorder and co-morbid depression Patients diagnosed with opioid use disorder initiating methadone treatment and... | 2025 | Case series (single-arm open-label feasibility trial) | n = 3 |